BioCentury
ARTICLE | Company News

BioDiem, Changchun BCHT deal

February 20, 2012 8:00 AM UTC

BioDiem granted Changchun exclusive rights to its live attenuated influenza virus (LIAV) technology for an egg-based production method for pandemic and seasonal influenza vaccines for the private market in China. BioDiem's LAIV technology delivers a vaccine through a nasal spray, which eliminates the need for injections. Changchun already has a sublicense to the LAIV technology for the public market in China from the World Health Organization under WHO's Pandemic Flu program. Details are not disclosed.

Last year, BioDiem regained from the Nobilon International B.V. unit of Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.) worldwide rights, excluding the Commonwealth of Independent States (CIS), Japan and North America, to the LAIV technology. BioDiem said Merck returned rights as a result of the pharma's ongoing pipeline prioritization (see BioCentury, Aug. 8, 2011). ...